In the pharmaceutical industry, microneedle technology is reshaping the research and development paradigm of drug delivery systems. As an innovative transdermal drug delivery platform, it not only improves the efficacy and safety of existing drugs but also opens up an entirely new delivery pathway for biomolecular drugs that are difficult to administer via traditional routes, earning it the reputation of a disruptive technology in the pharmaceutical industry.

Microneedles deliver outstanding performance in enhancing drug bioavailability. Traditional transdermal patches are generally limited to molecules below 500 Daltons in molecular weight, while microneedles can successfully deliver biomacromolecules with a molecular weight up to 150 kDa. Studies show that the bioavailability of insulin delivered via microneedles reaches 85%–95% of subcutaneous injection levels, compared with less than 1% for conventional transdermal formulations. This breakthrough enables transdermal administration of peptides, proteins, antibodies and even nucleic acid drugs.

Pharmacokinetic regulation is another major advantage of microneedle formulations. By designing needle materials with different dissolution rates, sustained drug release ranging from several hours to weeks can be achieved. PLGA (polylactic-co-glycolic acid) microneedles support sustained release for up to 30 days, with a blood drug concentration fluctuation coefficient below 0.3 - far superior to daily oral or injectable administration. For psychiatric drug delivery, this stable release profile avoids peak-trough fluctuations in blood drug levels, reduces side effects and improves treatment adherence.

Combination drug delivery represents a unique capability of microneedle technology. Different needles within the same microneedle array can be loaded with distinct drugs to enable synergistic therapy. For instance, in diabetic wound healing, an all-in-one microneedle patch can be engineered to carry insulin (to promote glucose utilization), growth factors (to facilitate granulation tissue formation), and antibiotics (to prevent infection). Such spatiotemporally controlled combination delivery demonstrates immense potential in the treatment of complex diseases.

Microneedles stand out particularly prominently in vaccine formulation innovation. Conventional vaccines rely on cold-chain transportation and professional medical personnel for intramuscular injection. By contrast, microneedle vaccines remain stable long-term at room temperature and trigger stronger immune responses by targeting abundant skin antigen-presenting cells, including Langerhans cells and dendritic cells. Research indicates that influenza microneedle vaccines can deliver equivalent protective efficacy with only one-fifth the dose of intramuscular vaccines, while inducing broader cross-immunity. During the COVID-19 pandemic, the rapid deployability of microneedle vaccines was validated, cutting the timeline from production to administration by 60%.

Microneedle technology has made personalized pharmaceutical formulations feasible. 3D printing enables the fabrication of customized microneedle arrays tailored precisely to individual skin thickness, disease conditions and drug metabolic characteristics. The length, diameter and drug loading of each microneedle can be precisely controlled, realizing truly personalized medication customization. Clinical trials show that for psoriasis treatment, personalized microneedle formulations improve PASI scores by 40% compared with standard formulations, while reducing adverse reactions by 65%.

Pharmaceutical production workflows are also being revolutionized by microneedle technology. Large-scale microneedle manufacturing adopts micro-nano fabrication techniques such as micro-molding and micro-injection molding, enabling high-throughput output of tens of thousands of patches per hour. Compared with conventional injections, microneedle patches lower production energy consumption by 30%, raise raw material utilization by 25%, and eliminate the need for complicated packaging such as syringes and vials, thereby simplifying the entire supply chain.

In terms of clinical translation, microneedle formulations are advancing at an accelerated pace. As of early 2026, a total of 17 microneedle-based drugs worldwide have entered clinical trials, among which 3 have been approved for marketing. The microneedle formulation of GLP-1 receptor agonists for diabetes has completed Phase III clinical trials, demonstrating non-inferior blood glucose control compared with daily injections while reducing the incidence of gastrointestinal side effects by 50%. Fentanyl microneedle patches for analgesia provide 72-hour sustained pain relief for cancer patients, lowering the risk of abuse by 80% relative to conventional patches.

Regulatory science is also adapting to innovations in microneedle technology. In 2025, the FDA issued the Guidance for the Development and Evaluation of Microneedle Transdermal Drug Delivery Systems, clarifying special considerations for microneedle formulations: mechanical performance testing must simulate real-world use conditions; drug stability must account for physical pressure during skin penetration; biocompatibility assessment must cover the complete product lifecycle; and clinical endpoints should include local reactions such as skin irritation and pigmentation changes.

Nevertheless, microneedle-based pharmaceuticals still face considerable challenges. High costs remain a major limiting factor, with the production cost of each microneedle patch approximately 3–5 times that of conventional transdermal patches. Maintaining the stability of biomacromolecular drugs during microneedle manufacturing - especially molecules sensitive to temperature and shear force - continues to pose technical difficulties. In addition, long-term safety data regarding cumulative skin reactions and immunogenicity after prolonged use remain insufficient.

Future trends point toward deep integration between microneedles and digital health technologies. Intelligent patches embedded with microneedles can monitor real-time drug release rates, patient compliance and therapeutic outcomes, and transmit data wirelessly to medical teams. In mental health management, such closed-loop systems can automatically adjust drug release according to physiological indicators such as heart rate variability, enabling dynamically optimized treatment.